Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25293608 | 0.81 | SMN1; SMN2 (0.70) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL15396540 | 0.81 | SMN1; SMN2 (0.70) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL12686356 | 0.80 | SMN1; SMN2 (0.68) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL12260494 | 0.76 | SMN1; SMN2 (0.76) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL10850696 | 0.74 | SMN1; SMN2 (0.82) | RXFP1MAPTSMN1; SMN2ADORA2BMAPK1 | |
| SCHEMBL10178054 | 0.74 | SMN1; SMN2 (0.63) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL17635429 | 0.74 | SMN1; SMN2 (0.62) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL12686387 | 0.73 | MAPT (0.56) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL10178027 | 0.73 | SMN1; SMN2 (1.00) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B | |
| SCHEMBL25295543 | 0.73 | LMNA (0.56) | RXFP1MAPTTDP1SMN1; SMN2ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-12-03 | — | — | US | disclosed |
| WO-2019028308-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | AZI2, ATP6V1B1, GLS | RXFP1 4675/4885MAPT 4542/4885TDP1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.